A Phase 3 interventional study of E/C/F/TAF and DRV in HIV-1, HIV Infections and Acquired Immunodeficiency Syndrome, sponsored by Gilead Sciences. Completed at 62 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome — none open to participants now, 1 under way, 1 of them phase 3. Cobicistat · Acquired Immunodeficiency Syndrome.
Among the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome, this one is the 4th largest by enrollment, is one of 4 that started in 2013, is one of 5 in phase 3, and was the 7th registered.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →None of the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome is open now. The open studies under Acquired Immunodeficiency Syndrome, anywhere →
Cobicistat: first FDA approval 2012 (STRIBILD), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 7 · Phase 4 2
First in 2011; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 158 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 116 across the 16 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 16 have an industry lead sponsor. The 8 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
35 studies in Acquired Immunodeficiency Syndrome by Gilead Sciences: none open now, 1 under way, 1 of them phase 3. Of 34 finished, 19 (56%) have results posted.
Among the 35 studies in Acquired Immunodeficiency Syndrome by Gilead Sciences, this one is the 13th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2013, is one of 12 in phase 3, and was the 32nd registered.
Gilead Sciences’s Acquired Immunodeficiency Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 35 in Acquired Immunodeficiency Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed dose combination (FDC) plus darunavir (DRV) relative to current antiretroviral regimens (ARV) in virologically suppressed, HIV-1 positive participants with HIV-1 RNA \<50 copies/mL at Week 24.
This study consists of 48 weeks of open-label phase followed by an optional Extension Phase in which all the participants will receive E/C/F/TAF+DRV.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's enrollment of 158 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is HIV Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
A female individual is eligible to enter the study if it is confirmed that she is:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive E/C/F/TAF FDC + DRV once daily with food for 48 weeks. Based on safety and efficacy data from Cohort 1 at Week 4, the participants will be randomized into Cohort 2. The participants in Cohort 1 will continue receiving E/C/F/TAF FDC + DRV through 48 weeks.
Drug: E/C/F/TAF · Drug: DRV
Participants will be randomized to receive E/C/F/TAF FDC+DRV once daily with food for 48 weeks.
Drug: E/C/F/TAF · Drug: DRV
Participants will be randomized to continue on their baseline DRV-containing ARV regimen for 48 weeks.
Drug: Baseline DRV- containing ARV regimen
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
150/150/200/10 mg FDC tablet administered orally once daily
Also known as: Genvoya®
800 mg tablet administered orally once daily
Participants will take their baseline DRV- containing ARV regimen as prescribed.
Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 24
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 48
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Change From Baseline in CD4+ Cell Count at Week 24
Time frame: Baseline; Week 24
Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline; Week 48
Participants were enrolled at study sites in the United States and Canada. The first participant was screened on 3 September 2013. The last study visit occurred on 09 July 2016.
| Milestone | Cohort 1: E/C/F/TAF+DRV | Cohort 2: E/C/F/TAF+DRV | Cohort 2: Stay on Baseline Regimen (SBR) |
|---|---|---|---|
| Started | 22 | 90 | 46 |
| Completed | 20 | 87 | 41 |
| Not completed | 2 | 3 | 5 |
| Withdrew: Randomized but never treated | 1 | 1 | 0 |
| Withdrew: Investigator's discretion | 0 | 1 | 0 |
| Withdrew: Withdrew consent | 1 | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Milestone | Cohort 1: E/C/F/TAF+DRV | Cohort 2: E/C/F/TAF+DRV | Cohort 2: Stay on Baseline Regimen (SBR) |
|---|---|---|---|
| Started | 20 | 87 | 34 |
| Completed | 19 | 86 | 30 |
| Not completed | 1 | 1 | 4 |
| Withdrew: Adverse event | 0 | 0 | 2 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Cohort 2: E/C/F/TAF+DRV | Cohort 2: Stay on Baseline Regimen (SBR) |
|---|---|---|
| Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 24 | 96.6 | 91.3 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Cohort 2: E/C/F/TAF+DRV | Cohort 2: Stay on Baseline Regimen (SBR) |
|---|---|---|
| Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 48 | 94.4 | 76.1 |
| cells/μL | Cohort 2: E/C/F/TAF+DRV | Cohort 2: Stay on Baseline Regimen (SBR) |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 24 | 23 ± 155.2 | 12 ± 100.9 |
| cells/μL | Cohort 2: E/C/F/TAF+DRV | Cohort 2: Stay on Baseline Regimen (SBR) |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 48 | 5 ± 162.6 | 41 ± 104.2 |
Collected over Up to a maximum of 97.4 weeks (duration of exposure: Cohort 1 and Cohort 2 = 48 weeks; All E/C/F/TAF = up to maximum of 97.4 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: E/C/F/TAF+DRV | — | 1/21 (4.8%) | 13/21 (61.9%) |
| Cohort 2: E/C/F/TAF+DRV | — | 9/89 (10.1%) | 56/89 (62.9%) |
| Cohort 2: SBR | — | 1/46 (2.2%) | 28/46 (60.9%) |
| All E/C/F/TAF | — | 20/144 (13.9%) | 104/144 (72.2%) |
| Event | Cohort 1: E/C/F/TAF+DRV | Cohort 2: E/C/F/TAF+DRV | Cohort 2: SBR | All E/C/F/TAF |
|---|---|---|---|---|
| Pneumonia bacterialInfections and infestations | 1/21 | 0/89 | 0/46 | 1/144 |
| Vascular pseudoaneurysmInjury, poisoning and procedural complications | 0/21 | 0/89 | 1/46 | 0/144 |
| Small intestinal obstructionGastrointestinal disorders | 0/21 | 1/89 | 0/46 | 2/144 |
| Chest painGeneral disorders | 0/21 | 1/89 | 0/46 | 2/144 |
| TachycardiaCardiac disorders | 0/21 | 1/89 | 0/46 | 1/144 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 0/21 | 1/89 | 0/46 | 1/144 |
| PancreatitisGastrointestinal disorders | 0/21 | 1/89 | 0/46 | 1/144 |
| Retroperitoneal haemorrhageGastrointestinal disorders | 0/21 | 1/89 | 0/46 | 1/144 |
| Non-cardiac chest painGeneral disorders | 0/21 | 1/89 | 0/46 | 1/144 |
| BronchitisInfections and infestations | 0/21 | 1/89 | 0/46 | 1/144 |
| Event | Cohort 1: E/C/F/TAF+DRV | Cohort 2: E/C/F/TAF+DRV | Cohort 2: SBR | All E/C/F/TAF |
|---|---|---|---|---|
| Acute sinusitisInfections and infestations | 4/21 | 1/89 | 0/46 | 9/144 |
| Upper respiratory tract infectionInfections and infestations | 3/21 | 10/89 | 2/46 | 27/144 |
| BronchitisInfections and infestations | 3/21 | 6/89 | 1/46 | 14/144 |
| SinusitisInfections and infestations | 3/21 | 6/89 | 4/46 | 15/144 |
| Back painMusculoskeletal and connective tissue disorders | 0/21 | 11/89 | 3/46 | 12/144 |
| HeadacheNervous system disorders | 1/21 | 6/89 | 0/46 | 16/144 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 2/21 | 2/89 | 1/46 | 7/144 |
| Oral candidiasisInfections and infestations | 2/21 | 1/89 | 0/46 | 3/144 |
| Otitis mediaInfections and infestations | 2/21 | 3/89 | 0/46 | 7/144 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/21 | 3/89 | 2/46 | 7/144 |
Safety analysis set included: * Cohort 1: participants who (1) were enrolled into Cohort 1 and (2) received at least 1 dose of study drug during the OL Phase or the Extension Phase * Cohort 2: participants who (1) were randomized into Cohort 2 and (2) received at least 1 dose of study drug during the OL Phase or the Extension Phase
| Age, Continuous(Years) | Cohort 1: E/C/F/TAF+DRV | Cohort 2: E/C/F/TAF+DRV | Cohort 2: SBR | Total |
|---|---|---|---|---|
| Mean | 53 ± 5.7 | 49 ± 8.2 | 47 ± 9.4 | 49 ± 8.4 |
| Sex: Female, Male(Participants) | Cohort 1: E/C/F/TAF+DRV | Cohort 2: E/C/F/TAF+DRV | Cohort 2: SBR | Total |
|---|---|---|---|---|
| Female | 8 | 16 | 18 | 42 |
| Male | 13 | 73 | 28 | 114 |
| Race/Ethnicity, Customized(participants) | Cohort 1: E/C/F/TAF+DRV | Cohort 2: E/C/F/TAF+DRV | Cohort 2: SBR | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 0 | 1 | 0 | 1 |
| Black | 12 | 35 | 26 | 73 |
| Native Hawaiian or Pacific Islander | 0 | 1 | 0 | 1 |
| White | 9 | 51 | 17 | 77 |
| Not Permitted | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 3 | 3 |
| Race/Ethnicity, Customized(participants) | Cohort 1: E/C/F/TAF+DRV | Cohort 2: E/C/F/TAF+DRV | Cohort 2: SBR | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 12 | 7 | 21 |
| Not Hispanic or Latino | 19 | 77 | 39 | 135 |
| Not Permitted | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort 1: E/C/F/TAF+DRV | Cohort 2: E/C/F/TAF+DRV | Cohort 2: SBR | Total |
|---|---|---|---|---|
| Canada | 0 | 9 | 3 | 12 |
| United States | 21 | 80 | 43 | 144 |
| HIV-1 RNA Category(participants) | Cohort 1: E/C/F/TAF+DRV | Cohort 2: E/C/F/TAF+DRV | Cohort 2: SBR | Total |
|---|---|---|---|---|
| < 50 copies/mL | 19 | 87 | 46 | 152 |
| ≥ 50 copies/mL | 2 | 2 | 0 | 4 |
| CD4 Cell Count(cells/µL) | Cohort 1: E/C/F/TAF+DRV | Cohort 2: E/C/F/TAF+DRV | Cohort 2: SBR | Total |
|---|---|---|---|---|
| Mean | 700 ± 372.5 | 562 ± 260.8 | 571 ± 245.2 | 583 ± 275.9 |
| CD4 Cell Count Category(participants) | Cohort 1: E/C/F/TAF+DRV | Cohort 2: E/C/F/TAF+DRV | Cohort 2: SBR | Total |
|---|---|---|---|---|
| < 200 cells/µL | 1 | 5 | 1 | 7 |
| ≥ 200 to < 350 cells/µL | 3 | 15 | 7 | 25 |
| ≥ 350 cells/µL | 17 | 69 | 38 | 124 |
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Sep 2013 to primary completion in Jul 2015, 22 months.
Results were first posted in Nov 2016, 1 year 3 months after primary completion. A results delay was requested in Apr 2015.
Of 34 industry-sponsored phase 3 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's 22 months is close to that.
Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 19 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide · Darunavir
Acquired Immunodeficiency Syndrome →